Articles from Gastrointestinal Tumors are provided here courtesy of Karger Publishers. A recently published subgroup analysis of the ESPAC-3 trial suggests that the treatment duration 6 months and the associated dose intensity are more relevant than a very early within 6 weeks initiation of treatment after surgery. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Cancer statistics, Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer:
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate PEP02, MM for patients with gemcitabine-refractory metastatic pancreatic cancer.
To improve this outcome a neoadjuvant treatment strategy may be helpful, and several small trials have been conducted [ 567891011 ]. Ann Surg. Projecting cancer incidence and deaths to
Phase III trial comparing intensive induction chemoradiotherapy 60 Gy, infusional 5-FU and intermittent cisplatin followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.